Moderna, Inc.
135.61USD
-4.7200 (-3.36%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 19.3B | 6.8B | 3.2B | 1.9B | 2.1B | 2.4B |
| Q1 | 6.1B | 1.9B | 167.0M | 108.0M | 389.0M | — |
| Q2 | 4.7B | 344.0M | 241.0M | 142.0M | 145.0M | — |
| Q3 | 3.4B | 1.8B | 1.9B | 1.0B | 895.0M | — |
| Q4 | 5.1B* | 2.8B* | 966.0M* | 678.0M* | 667.8M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 20.12 | -12.33 | -9.28 | -7.26 | -8.41 | -4.93 |
| Q1 | 8.58 | .190 | -3.07 | -2.52 | -3.40 | — |
| Q2 | 5.24 | -3.62 | -3.33 | -2.13 | -1.97 | — |
| Q3 | 2.53 | -9.53 | .030 | -.510 | -1.29 | — |
| Q4 | 3.52* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .568* |
| -2.92* |
| -2.12* |
| -1.74 |
| — |